目次

1. Introduction to Bispecific Monoclonal Antibody

2. Advantage of Bispecific Antibodies Over Monospecific Monoclonal Antibodies

3. Bispecific Antibodies - Development Process and Mechanism of Action
3.1 Development of Bispecific Antibodies Similar to IgG
3.2 Development of Small Bispecific Antibodies
3.3 General Mechanism of Bispecific Antibodies

4. Approved Bispecific Antibodies Mechanism of Action
4.1 Hemlibra
4.2 Blincyto
4.3 Reybrevant
4.4 Vabysmo
4.5 Lunsumio

5. Application of Bispecific Antibodies in Cancer
5.1 Cancer Diagnosis
5.2 Cancer Targeting By Blocking Signaling Pathways
5.3 Targeting Tumor Angiogenesis for Cancer Treatment

6. Miscellaneous Application of Bispecific Antibodies
6.1 Diagnosis of Microbial Infectious Diseases
6.2 Specific Delivery of Effector Compounds to Targets
6.3 Bispecific Antibodies as Genetic Antibody Therapy

7. Global and Regional Bispecific Antibody Market Outlook
7.1 Yearly and Quarterly Market Size Indicators
7.2 Approved Bispecific Antibodies Reimbursement Policy
7.2.1 Blincyto Reimbursement Policy
7.2.2 Hemlibra Reimbursement Policy
7.2.3 Rybrevant Reimbursement Policy
7.2.4 Vabysmo Reimbursement Policy
7.3 Global Bispecific Antibody Market Future Prospects

8. Blincyto: First Approved Bispecific Antibody 2015
8.1 Dosage and Price Analysis
8.2 Global and Regional Sales Analysis

9. Hemlibra: Second Approved Bispecific Antibody 2018
9.1 Dosage and Price Analysis
9.2 Global and Regional Sales Analysis

10. Rybrevant: Third Approved Bispecific Antibody 2021
10.1 Dosage and Price Analysis
10.2 Global and Regional Sales Analysis

11. Vabysmo: Forth Approved Bispecific Antibody 2022
11.1 Dosage and Price Analysis
11.2 Global and Regional Sales Analysis

12. Lunsumio: Fifth Approved Bispecific Antibody 2022

13. Cadonilimab: Sixth Approved Bispecific Antibody 2022

14. Tecvayli: Seventh Approved Bispecific Antibody 2022

15. Global Bispecific Antibodies Clinical Pipeline Overview
15.1 By Phase
15.2 By Country/Region
15.3 By Company
15.4 By Indication
15.5 Orphan Designated Bispecific Antibodies
15.6 Patient Segment

16. Global Bispecific Antibodies Clinical Pipeline By Company, Indication and Phase
16.1 Research
16.2 Preclinical
16.3 Phase-I
16.4 Phase-I/II
16.5 Phase-II
16.6 Phase-II/III
16.7 Phase-III
16.8 Registered

17. Marketed Bispecific Antibodies Clinical insight

18. Competitive Landscape
18.1 Ablynx
18.2 Adimab
18.3 Affimed Therapeutics
18.4 Amgen
18.5 AstraZeneca (MedImmune)
18.6 Chugai Pharmaceutical
18.7 Eli Lilly
18.8 EMD Serono
18.9 Emergent BioSolutions
18.10 Genentech
18.11 Genmab
18.12 Immunomedics
18.13 Jounce Therapeutics
18.14 MacroGenics
18.15 Merus
18.16 Neovii Biotech
18.17 NovImmune SA
18.18 OncoMed Pharmaceuticals
18.19 Pieris
18.20 Regeneron Pharmaceuticals
18.21 Roche
18.22 Sanofi

List of Figures & Tables
Figure 2-1: Advantages of Bispecific Antibodies
Figure 3-1: Types of Approaches to Form IgG like Bispecific Antibodies
Figure 3-2: Method of Formation of Hybrid Hybridoma
Figure 3-3: Limitations of Hybrid Hybridoma
Figure 3-4: Steps involved in “Knobs into Holes” Approach
Figure 3-5: Three different CrossMabs are Obtained by Three Different Modifications
Figure 3-6: Method for formation of Dual-Variable-Domain Immunoglobulin
Figure 3-7: Advantages of Dual Variable Domain Immunoglobulin approach
Figure 3-8: Types of Bispecific Antibodies
Figure 3-9: Bispecific Antibodies - General Mechanism of Action
Figure 3-10: Bispecific Antibodies: Pathways for Induction of Cytotoxicity
Figure 4-1: Hemlibra - Mechanism of Action
Figure 4-2: Blincyto - Mechanism of Action
Figure 4-3: Rybrevant - Mechanism of Action
Figure 5-1: Application of Bispecific Antibodies in Cancer
Figure 7-1: Global - Bispecific Antibody Market Size (US$ Million), 2016 - 2022*
Figure 7-2: Global - Bispecific Antibody Market Size (US$ Million), Q1’2022 and Q2’2022
Figure 7-3: Global - Bispecific Antibody Market Size by Region (US$ Million), H1’2022
Figure 7-4: Global - Bispecific Antibody Market Size by Region (%), H1’2022
Figure 7-5: Global - Bispecific Antibody Market Size by Region (US$ Million), 2021
Figure 7-6: Global - Bispecific Antibody Market Size by Region (%), 2021
Figure 7-7: US - Bispecific Antibody Market Size (US$ Million), 2016 - 2022
Figure 7-8: US - Bispecific Antibody Market Size (US$ Million), Q1’2022 and Q2’2022
Figure 7-9: ROW - Bispecific Antibody Market Size (US$ Million), 2016 - 2022*
Figure 7-10: ROW - Bispecific Antibody Market Size (US$ Million), Q1’2022 and Q2’2022
Figure 7-11: Bispecific Antibody Market Size by Region (US$ Million), 2020
Figure 7-12: Bispecific Antibody Market Size by Region (%), 2020
Figure 7-13: Global - Bispecific Antibody Market Size (US$ Million) by Products (Blincyto and Hemlibra), 2018 - 2021
Figure 7-14: Bispecific Antibody Market Size by Product (%), 2021
Figure 7-15: Bispecific Antibody Market Size by Product (%), 2020
Figure 7-16: Bispecific Antibody Market Size by Product (%), 2019
Figure 7-17: Blincyto - Total Treatment Cost and Reimbursement Cost
Figure 7-18: Blincyto - In Pocket and Out of Pocket Cost of Treatment
Figure 7-19: Hemlibra - Total Treatment Cost and Reimbursement Cost
Figure 7-20: Hemlibra - In Pocket and Out of Pocket Cost of Treatment
Figure 7-21: Global - Rybrevant Maximum Coverage by Medicaid (US$), 2021
Figure 7-22: Global - Rybrevant Maximum Coverage by Private Insurance Coverage (US$), 2021
Figure 7-23: Vabysmo - Total Treatment Cost and Reimbursement Cost
Figure 7-24: Vabysmo - In Pocket and Out of Pocket Cost of Treatment
Figure 7-25: Global - Bispecific Antibody Market Opportunity Assessment (US$ Billion), 2022 - 2028
Figure 8-1: Blincyto - Recommended Number of Induction and Consolidation Cycles for Treatment of MRD+ B-cell precursor ALL
Figure 8-2: Blincyto - Duration of Treatment Phase and Resting Phase in Induction and Consolidation Cycles for Treatment of MRD+ B-cell Precursor ALL (Days)
Figure 8-3: Blincyto - Cost of Single Cycle and Full Treatment Cost of MRD+ B-Cell Precursor ALL (US$), August’2022
Figure 8-4: Blincyto - Recommended Number of Induction and Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 8-5: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle and Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 8-6: Blincyto - Cost of 1st and 2nd Induction Cycle for Treatment of Relapsed B- Cell Precursor ALL (US$), August’2022
Figure 8-7: Blincyto - Cost of Different Treatment Phases and Full Treatment Cost for Relapsed B-Cell Precursor ALL (US$), August’2022
Figure 8-8: Global - Blincyto Sales Value (US$ Million), 2015 - 2022*
Figure 8-9: US - Blincyto Sales Value (US$ Million), 2016 - 2022*
Figure 8-10: ROW - Blincyto Sales Value (US$ Million), 2016 - 2022*
Figure 8-11: Blincyto - US v/s Rest of World Share in Sales Value (US$ Million), H1’2022
Figure 8-12: Global - Blincyto Sales Value (US$ Million), Q1’2022 and Q2’2022
Figure 8-13: Global - Blincyto Sales Value by Region (US$ Million), Q2’2022
Figure 8-14: Global - Blincyto Sales Value by Region (%), Q2’2022
Figure 8-15: Global - Blincyto Sales Value by Region (US$ Million), Q1’2022
Figure 8-16: Global - Blincyto Sales Value by Region (%), Q1’2022
Figure 8-17: Global - Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 8-18: US - Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 8-19: ROW - Blincyto Quarterly Sales Value (US$ Millions), Q1-Q4’2021
Figure 8-20: Blincyto - US v/s Rest of World Share in Sales Value (US$ Million), 2021
Figure 8-21: Blincyto - US v/s Rest of World Share in Sales Value (%), 2021
Figure 8-22: US - Blincyto Half Yearly Sales (US$ Millions), H1’2021 and H1’2022
Figure 8-23: ROW - Blincyto Half Yearly Sales (US$ Millions), H1 2021 and H1 2022
Figure 8-24: Global - Blincyto Quarterly Sales Value (US$ Millions), 2020
Figure 8-25: Blincyto - Quarterly Sales Value (US$ Million), 2019
Figure 8-26: Blincyto - Quarterly Sales Value (US$ Million), 2018
Figure 8-27: Blincyto - US v/s Rest of World Share in Sales Value (%), 2020
Figure 8-28: Blincyto - US v/s Rest of World Share in Sales Value (%), 2019
Figure 8-29: Blincyto - US v/s Rest of World Share in Sales Value (%), 2018
Figure 9-1: Hemlibra - Cost for Single Unit of 30mcg and 150mcg Subcutaneous Injection (US$), August’2022
Figure 9-2: Hemlibra - Recommended Loading and Maintenance Dose for Treatment of Hemophilia (mg/Kg/Week)
Figure 9-3: Hemlibra - Average Monthly and Annual Cost for Treatment of Hemophilia A (US$), August’2022
Figure 9-4: Global - Hemlibra Sales Value by Region (US$/ CHF Million), H1’2022
Figure 9-5: Global - Hemlibra Sales Value by Region (US$/ CHF Million), H1’2022
Figure 9-6: Global - Hemlibra Sales Value by Region (US$/ CHF Million), Q1’2022
Figure 9-7: Global - Hemlibra Sales Value by Region (US$/ CHF Million), Q1’2022
Figure 9-8: Global - Hemlibra Sales Value by Region (US$/ CHF Million), Q2’2022
Figure 9-9: Global - Hemlibra Sales Value by Region (US$/ CHF Million), Q2’2022
Figure 9-10: Global - Hemlibra Quarterly Sales Value (US$/ CHF Million), Q1-Q4’ 2021
Figure 9-11: US - Hemlibra Quarterly Sales Value (US$/ CHF Million), Q1-Q4’ 2021
Figure 9-12: Europe - Hemlibra Quarterly Sales Value (US$/ CHF Million), Q1-Q4’2021
Figure 9-13: Japan - Hemlibra Quarterly Sales Value (US$/ CHF Million), Q1-Q4’2021
Figure 9-14: ROW - Hemlibra Quarterly Sales Value (US$/CHF Million), Q1-Q4’2021
Figure 9-15: Global - Hemlibra Half Yearly Sales Value (US$/ CHF Million), H1 2020 and H1 2021
Figure 9-16: Hemlibra - Annual Sales Value by Region (US$/CHF Million), 2021
Figure 9-17: Hemlibra - Annual Sales Value by Region (%), 2021
Figure 9-18: Hemlibra - Half Yearly Sales Value by Region (US$/CHF Million), H1 2021
Figure 9-19: Hemlibra - Half Yearly Sales Value by Region (%), H1 2021
Figure 9-20: Global - Hemlibra Sales Value (US$ Million), 2018 - 2021
Figure 9-21: US- Hemlibra Sales Value (US$ Million), 2018 - 2021
Figure 9-22: Europe- Hemlibra Sales Value (US$ Million), 2018- 2021
Figure 9-23: Japan- Hemlibra Sales Value (US$ Million), 2018 - 2021
Figure 9-24: Hemlibra - Sales Value by Countries (US$ Million), 2020
Figure 9-25: Hemlibra - Sales Growth by Countries (%), 2020
Figure 9-26: Hemlibra - Sales Growth by Countries (US$ Million), 2019
Figure 9-27: Hemlibra - Sales Value by Countries (US$ Million), 2018
Figure 9-28: Hemlibra - Sales Value Share by Countries (%), 2020
Figure 9-29: Hemlibra - Sales Value Share by Countries (%), 2019
Figure 9-30: Hemlibra - Sales Value Share by Countries (%), 2018
Figure 9-31: Global - Hemlibra Quarterly Sales Value (US$ Million), 2018
Figure 9-32: Global - Hemlibra Half Yearly Sales Value (US$ Million), 2018 and 2019
Figure 9-33: Hemlibra - Half Year Sales Value by Countries (US$ Million), 2018 and 2019
Figure 9-34: Hemlibra - Quarterly Sales Value (US$ Million), 2019
Figure 9-35: Hemlibra - 9 Months Sales Value by Countries (US$ Million), 2019
Figure 9-36: Hemlibra - 9 Month Sales Value Share by countries (%), 2019
Figure 10-1: Rybrevant - Price for 7ml Supply and Price per Unit of 50mg/ml Intravenous Solution (US$), August’2022
Figure 10-2: Rybrevant - Recommended Dose Per Cycle by Body Weight (mg)
Figure 10-3: Rybrevant - Dose Reduction in Patients with Weight Less Than 80Kg (mg)
Figure 10-4: Rybrevant - Dose Reduction in Patients with Weight More Than 80Kg (mg)
Figure 10-5: Global - Rybrevant Sales Forecast (US$ Million), 2021-2028
Figure 10-6: US - Rybrevant Sales Forecast (US$ Million), 2021-2028
Figure 10-7: ROW - Rybrevant Sales Forecast (US$ Million), 2022-2028
Figure 11-1: Vabysmo - Price for 0.05ml Supply and Price per Unit of 6mg/0.05ml Intravitreal Solution (US$), August’2022
Figure 11-2: Vabysmo - Cost of Single Cycle and Monthly Cost of Treatment (US$) August’2022
Figure 11-3: Global - Vabysmo Sales Value by Region (US$/ CHF Million), Q2’2022
Figure 11-4: Global - Vabysmo Sales Value by Region (US$/ CHF Million), Q2’2022
Figure 15-1: Global - Bispecific Antibodies Clinical Pipeline by Phase (Numbers), 2021 till 2028
Figure 15-2: Global - Bispecific Antibodies in Clinical Pipeline by Country (Numbers), 2022 till 2028
Figure 15-3: Global - Bispecific Antibodies in Clinical Pipeline by Company (Numbers), 2022 till 2028
Figure 15-4: Global - Bispecific Antibodies in Clinical Pipeline by Indication (Numbers), 2022 till 2028
Figure 15-5: Global - Bispecific Antibodies in Clinical Pipeline by Orphan Status (Numbers), 2022 till 2028
Figure 15-6: Global - Bispecific Antibodies in Clinical Pipeline by Patient Segment (Numbers), 2022 till 2028
Figure 18-1: Ablynx - Clinical Pipeline
Figure 18-2: Affimed Therapeutics - Clinical Pipeline
Figure 18-3: Amgen - Clinical Pipeline
Figure 18-4: EMD Serono - Clinical Pipeline
Figure 18-5: Emergent Bioscience - Clinical Pipeline
Figure 18-6: Genmab - Clinical Pipeline
Figure 18-7: Jounce Therapeutics - Clinical Pipeline
Figure 18-8: MacroGenics - Clinical Pipeline
Figure 18-9: Merus - Clinical Pipeline
Figure 18-10: Novimmune - Clinical Pipeline
Figure 18-11: OncoMed - Clinical Pipeline
Figure 18-12: Pieris Pharmaceuticals - Clinical Pipeline
Figure 18-13: Roche - Clinical Pipeline
Table 3-1: List of Bispecific Antibodies Formed by Hybrid Hybridoma Method
Table 3-2: List of Bispecific Antibodies Formed by DART
Table 3-3: List of Bispecific Antibodies Formed by BiTE Method
Table 3-4: List of Other BiTEs
Table 5-1: Bispecific Antibodies Targeting Cancer